Canadian firm Genix has acquired 30 ophthalmic generic dossiers from Canagen. Genix expects to begin commercialization from 2022.
Canada’s Genix Pharmaceuticals has completed a deal to acquire 30 ophthalmic generic dossiers from Canagen, in exchange for 15 million shares issued to Canagen shareholders, valued at $750,000 in total.
“The acquisition represents a milestone for the company to continue to enhance its portfolio of high-growth, high-margin pharmaceutical and nutraceutical...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
